Paliperidone 6-Month Im Injection
Form: Once-6-Month IM Injection
Strength: 1,092 mg, 1,560 mg
Reference Brands: Invega Hafyera®(US)
Category: Antipsychotropic Drugs
Paliperidone 6-month intramuscular injection (brand name: Invega Hafyera) is FDA-approved in the United States for the maintenance treatment of schizophrenia in adults stabilized on 1-month or 3-month paliperidone formulations. It is designed to improve adherence and reduce relapse by offering long-term dosing. In the European Union, this 6-month version is not yet widely approved, requiring a new EMA submission via the centralized procedure. Regulatory requirements include GMP-compliant long-acting injectable technology, bridging pharmacokinetic studies, and thorough safety evaluations. U.S. labelling carries boxed warnings for elderly dementia-related psychosis. Explore sourcing options at Pharmatradz.com — your B2B pharma partner.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Risperidone Long-Acting Injection
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes
Form: Long-Acting Injection
Reference Brands: Risperdal Consta(US &EU)
View Details
Zuclopenthixol Ong-Acting Im Injection (Depot)
Strength: 200 mg/mL, 500 mg/mL
Form: Long-acting IM Injection (Depot)
Reference Brands: Clopixol Depot®(US)
View Details
Zuclopenthixol Short-Acting Intramuscular Injection
Strength: 50 mg/mL
Form: Short-acting Intramuscular Injection
Reference Brands: Clopixol-Acuphase®
View Details
Zuclopenthixol Tablets
Strength: 10 mg, 25 mg, 40 mg
Form: Oral Tablets
Reference Brands: Clopixol®(EU)
View Details